E. David Crawford, MD, head of urologic oncology and a professor at the University of Colorado School of Medicine in Denver spoke with Renal & Urology News about the benefits of a new method that could potentially limit the number of unnecessary repeat biopsies.

ConfirmMDx, an epigenetic assay developed by MDxHealth, uses an epigenetic field effect (“halo”) to determine the risk of cancerization at a DNA level. The innovative test can help to single out men without a risk of prostate cancer from undergoing unnecessary biopsies as well as identify patients who need treatment.